Investigational drug · Phase 3
Maolactin
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Muscle Pain, Chronic Inflammation, Mobility.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
3
Any phase or sponsor naming "Maolactin"
First trial start
2024
Feb 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Maolactin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Muscle Pain
- Chronic Inflammation
- Mobility
- Joint Pain
- Gastrointestinal Dysfunction
- Post Exercise Inflammation
- Exercise Recovery
- Muscle Fatigue
Approved drugs for the same conditions: Gastroenterology and liver · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Maolactin" as an intervention, largest first.
- Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy PopulationPivotal-lookingCompleted
RDC Clinical Pty LtdIndustry
NCT06444763 · 97 participants · Start Feb 27, 2025 · Primary completion Feb 16, 2026
Drug: Maolactin; Maltodextrin · For: Chronic Inflammation; Mobility; Muscle Pain and 1 more
Sites: Brisbane, Australia
- Effect of Maolactin on Gastrointestinal Tract (GIT) HealthPivotal-lookingCompleted
RDC Clinical Pty LtdIndustry
NCT06104917 · 91 participants · Start Feb 21, 2024 · Primary completion Jul 23, 2025
Drug: High Dose Maolactin; Low Dose Maolactin and 1 more · For: Gastrointestinal Dysfunction
Sites: Brisbane, Australia
- Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy PopulationPivotal-lookingCompleted
RDC Clinical Pty LtdIndustry
NCT06436781 · 33 participants · Start Sep 12, 2024 · Primary completion May 23, 2025
Drug: Maolactin; Maltodextrin · For: Post Exercise Inflammation; Exercise Recovery; Muscle Fatigue and 1 more
Sites: Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Muscle Pain
- MaltodextrinPhase 34 trials
RDC Clinical Pty Ltd · Muscle Pain, Chronic Inflammation, Mobility
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.